

## Index

---

- abdominal circumference (AC) 153
- abdominal decompression 163–5
- abscess, cerebral 341
- academic function, asphyxia outcomes 844
- acidemia 239–40, 403, 598
  - detection 240–1
  - isovaleric (IVA) 403
  - methylmalonic (MMA) 403
  - propionic (PA) 403
- acidosis 9–11, 58, 96–8, 593–607
  - fetal compromise and 83, 96–8, 105
  - hypoxic–ischemic brain injury and 602–7
  - lactic acidosis 401–3, 602–3
  - management 137
    - bicarbonate use in neonatal resuscitation 683–4
  - metabolic acidosis 593
    - effect on cerebral blood flow 598–9
    - effect on cerebral metabolism 601–2
    - hypoxic–ischemic brain injury and 602–4
    - long-term outcome 840–1
  - outcome relationships 83
  - respiratory acidosis 593
    - effect on cerebral blood flow 593–8
    - effect on cerebral metabolism 599–601
    - hypoxic–ischemic brain injury and 604–6
- aciduria
  - fumaric 401
  - glutaric 403
  - 3-hydroxyisobutyric 403
  - mevalonic 400, 404
- acquired immunodeficiency syndrome (AIDS) 377, 378, 385–6
  - development time 382–3
  - see also* human immunodeficiency virus (HIV)
- activin, neuroprotective role 723
- acute fatty liver of pregnancy (AFLP) 259, 261
- Addison's disease 196
- adenosine
  - neuroprotective role 718
  - persistent pulmonary hypertension treatment 642

## 888 Index

- adenosine triphosphate (ATP) 58–61, 62
- adrenal disorders, maternal 196–7  
congenital adrenal hyperplasia 196–7
- adrenaline *see* epinephrine
- Aicardi syndrome 440  
EEG recordings 440
- AIDS *see* acquired immunodeficiency syndrome
- alanine aminotransferase (ALT) 545
- alcohol abuse 199–200, 276–9  
alcohol in breast milk 278–9  
fetal alcohol syndrome (FAS) 200, 277–9  
intoxication 276  
teratogenic effects 277–8  
*see also* substance abuse
- alcohol ingestion 276  
IUGR and 151
- alkalemia 598
- alkalosis 593  
effect on cerebral blood flow 593–9  
effect on cerebral metabolism 599–602  
hypoxic–ischemic brain damage and 604–6  
ventilator management 640
- alloimmunization 201
- alpha-ketoglutarate dehydrogenase deficiency 401
- altitude, birth weight and 152
- Americans With Disabilities Act (1990) 866
- aminophylline, hemodynamic effects 499
- 21-aminosteroids 709
- amnioinfusion, labor management 137, 138
- amniotic fluid embolism (AFE) 261–3  
clinical manifestation 262  
differential diagnosis 263  
management 263  
outcome 263  
risk factors 262–3
- amphetamine abuse 288–9
- anemia  
Diamond–Blackfan anemia 202  
Fanconi's anemia 202  
IUGR association 157  
management 697–8  
sinusoidal patterns and 237
- anencephaly 111–13, 123  
termination period 111
- aneurysms, congenital 122
- angiotensinogen (AGT) gene 257–8
- animal models  
asphyxia  
brief repeated asphyxia 92–3  
pathological determinants of injury 98  
fetal responses to hypoxia 86–8, 216  
hypoglycemia 563–4  
hypoxic–ischemic encephalopathy 30–53, 65  
excitotoxic mechanisms 36–7, 47  
glutamate transporter defects 37–41  
Na,K-ATPase defects 45–8  
neuronal cell death 48–51  
neuronal signal transduction mechanisms 32–6  
NMDA receptor phosphorylation elevation 41–5  
striatal neuronal degeneration 37–48, 99, 100  
pulmonary injury 643
- annexin V radionucleotide scans 484–5
- antibiotic treatment  
chorioamnionitis 309–10  
congenital syphilis 365–6  
neonatal meningitis 341–4  
choice of antibiotics 342–3  
duration of treatment 343–4  
neonatal sepsis 318  
*Escherichia coli* 326–7  
group B streptococcus 322  
prophylaxis 324–5
- antidepressant drugs 199
- antiepileptic drugs (AEDs) 197–8, 775–7  
discontinuation 776–7  
efficacy 776  
*see also* epilepsy; seizures
- antiphospholipid (aPL) antibodies 204–5, 206
- antiviral therapy  
herpes simplex 371–2  
HIV 385, 386
- Apgar score 6, 239, 763
- apnea of prematurity 498
- apoptosis 48–51, 72–6, 716–17  
apoptosis–necrosis continuum 51–3  
*see also* cell death; neuronal degeneration
- aprosencephaly 116–17, 123
- L-arginine, persistent pulmonary hypertension treatment 642
- arteriovenous malformations (AVMs) 121  
intracranial hemorrhage 176
- aspartate aminotransferase (AST) 545
- asphyxia 3–5, 85, 129, 392, 395–6  
biochemical markers of 544–5  
causes of 83–4  
chorioamnionitis association 307  
correlative signs of 9–11  
fetal/neonatal blood gas levels 9–11  
meconium 9
- electronic fetal monitoring role in prediction 237–40
- fetal adaptations 85–6, 103–4
- fetal responses to 83, 84, 88–96, 232–3  
acute-on-chronic asphyxia 93–6  
maturational changes 93–6  
progressive asphyxia 91  
uterine contractions and brief repeated asphyxia 91–2
- follow-up 829–52
- incidence 6–8
- IUGR association 154–5

- laboratory correlated 11–12
- magnetic resonance imaging 465
- misuse of term 879–80
- multiple organ dysfunction 16–17
- nutritional support 798
- outcomes 6–9, 834–51
- academic function 844
  - case studies 849–51
  - cerebral palsy 835–7
  - cognitive ability 837–8, 843–4
  - early childhood outcome 834–40
  - epilepsy 838–9
  - growth 841
  - hearing loss 839–40
  - life expectancy 851
  - long-term outcome 841–51
  - microcephaly 840
  - motor skills 841–3
  - neonatal neurological examination related to early outcome 832–3
  - outcome measurements 834–5
  - psychoeducational ability 845–9
  - vision loss 839
- pathogenesis of cell death 84–5
- pathophysiological determinants of injury 98–103
- hypotension 98–9, 105
  - metabolic status 102
  - premature brain injury 100–2
  - repeated insults 99
  - temperature 102–3
- seizure etiology 760–3
- timing of 534, 540–8, 626–9
- EEG studies 543
  - fetal heart rate monitoring 542, 627
  - imaging studies 546–7
  - laboratory findings 543–5
  - meconium-stained amniotic fluid 542–3
  - neuropathological evaluations 547
  - newborn neurological evaluations 545–6
  - placental pathology 547
  - prepartum evaluation 541
  - seizures 543
- types of 5–6
- see also* hypoxia; hypoxic–ischemic encephalopathy (HIE)
- aspirin, IUGR prevention 165
- ataxia telangiectasia 202
- atelencephaly 116–17
- atropine, neonatal cardiac output enhancement 685
- auditory stimulation, hemodynamic effects 501
- autistic disorder, meconium-stained amniotic fluid association 617
- autoimmune disorders, maternal 202
- see also* systemic lupus erythematosus (SLE)
- avascular villi 522
- ‘Baby K’ case 860
- bacteremia, neonatal meningitis and 336–7
- see also* sepsis, neonatal
- bacterial vaginosis 305
- Bacteroides bivius*, chorioamnionitis 305
- barbiturates
- abuse 288
  - hypoxic–ischemic encephalopathy management 415, 706–7
- basal ganglia lesions 417–18
- benign familial neonatal seizures 773
- benzodiazepam, seizure management 775–6
- benzodiazepines
- abuse of 288
  - seizure management 775
- $\beta$ -oxidation of fatty acid disorders 260–1, 401–2
- bicarbonate, neonatal resuscitation and 683–4
- bilirubin neurotoxic effects 571–3
- see also* hyperbilirubinemia
- bilirubin-induced neurologic dysfunction (BIND) 571
- biophysical profile (BPP) 153, 220–1
- biparietal diameter (BPD) 153
- bipolar disease, maternal 199
- birth asphyxia *see* asphyxia
- birth weight 145
- altitude relationship 152
  - determination 132
  - smoking effects 279–80
- blood culture 316–17
- blood gas levels 9–11
- blood sugar measurement 553, 556
- see also* hyperglycemia; hypoglycemia
- blood transfusions
- exchange transfusion
    - hyperbilirubinemia management 575
    - polycythemia therapy 582
  - hemodynamic changes 500
  - transfusion-acquired HIV infection 382
- blood–brain barrier, neonatal meningitis and 337–8
- brachial plexus injury, shoulder dystocia and 266–7
- bradycardia 218, 234–7
- response to fetal asphyxia 89–90, 104–5
- brain
- development 112
    - EEG changes 430
    - maternal diabetes and 194
    - seizure consequences 777–8
    - time of rapid anatomical maturation 430
  - imaging, *see specific imaging techniques*
  - infarction
    - brain 17–18, 392, 416–17, 419–20
    - seizure etiology 765–8
  - malformations 111
    - diagnostic approach 123–4

## 890 Index

- brain (*cont.*)  
 seizure etiology 768–70  
 timing of 111  
 vascular 120–3  
*see also specific malformations*
- brain damage *see* asphyxia; encephalopathy; hypoxic–ischemic encephalopathy (HIE)
- brainstem lesions 418
- brainstem release phenomena 752
- breast milk, protection against necrotizing enterocolitis 803–4, 808, 809
- breastfeeding  
 HIV transmission 381  
 substance abuse and  
 alcohol 278–9  
 cocaine 286  
 nicotine 280  
 opioids 287–8
- breathing abnormalities 498
- bronchopulmonary dysplasia (BPD) 651, 694
- C-reactive protein (CRP)  
 in chorioamnionitis 303  
 neonatal meningitis and  
 diagnosis 339–40  
 treatment monitoring 344  
 neonatal sepsis diagnosis 317
- caffeine, IUGR and 152
- calbindin, neuroprotective role 718
- calcium  
 neonatal resuscitation 687–8  
 overload 65–8  
*see also* hypocalcemia
- calcium-channel blockers 708
- Campylobacter*, chorioamnionitis 305
- cannabis abuse 281–2
- capsular polysaccharide (CPS) antigens 320
- cardiac manifestations of asphyxia 16
- cardiac output  
 enhancement in neonatal resuscitation 680, 684–8  
 atropine 685  
 calcium 687–8  
 cardioversion and defibrillation 685  
 epinephrine 685  
 fluid resuscitation 685–7  
 inotropic drugs 687  
 isoproterenol 685  
 fetal regulation 228–31  
 maintenance in neonatal extended care 696–7  
 afterload reduction 697  
 inotropic drugs 696–7
- cardiac surgery 663–8  
 intraoperative period 664–6  
 circulatory arrest 664–5  
 hypothermia 665–6  
 postoperative period (reperfusion injury) 666–7  
 preoperative period 663–4  
 selective cerebral perfusion 668
- cardiopulmonary bypass (CPB), near-infrared spectroscopy (NIRS)  
 applications 503–5
- cardiotocography *see* nonstress test (NST)
- cardiovascular surgery, near-infrared spectroscopy (NIRS)  
 applications 503–5
- cardioversion, neonatal resuscitation 685
- carnitine palmitoyl transferase II (CPT II) deficiency 402
- carnitine-acylcarnitine translocase (CAT) deficiency 402
- carotid artery malformations 122–3
- causation 875
- cell death 48, 71  
 biphasic 715–16  
 mechanisms 716–17  
 pathogenesis of 84–5  
*see also* apoptosis; necrosis; neuronal degeneration
- cerebellar lesions 418–19  
 sclerosis 418–19
- cerebral abscess 341
- cerebral artery occlusion 419–20
- cerebral blood flow (CBF)  
 autoregulation 449, 666  
 Doppler studies 448–9  
 effects of therapies 449  
 pulsatility index (PI) 449  
 resistive index (RI) 448–9  
 hyperventilation and 640, 644  
 hypoglycemia relationship 567  
 intracranial hemorrhage and 178–9  
 metabolic acidosis/alkalosis effect 598–9  
 near-infrared spectroscopy (NIRS) measurement 494, 495–6  
 correlation with outcome 502–3  
 during intensive care 498–500  
 reperfusion injury 666–7  
 respiratory acidosis/alkalosis effect 593–8  
 responses to fetal asphyxia 88–9  
 responses to fetal hypoxia 86–7, 88  
 selective cerebral perfusion (SCAP) 663, 668  
*see also* deep hypothermic circulatory arrest (DHCA)
- cerebral blood volume (CBV) 494, 496  
 correlation with outcome 502–3  
 during intensive care 498–500
- cerebral blood volume reactivity (CBVR) 496, 503
- cerebral edema 415, 481, 545  
 computed tomography 463  
 management 704–6  
 corticosteroids 705–6  
 hyperventilation 704–5  
 mannitol 706
- cerebral metabolism  
 hypothermia and 665  
 metabolic acidosis/alkalosis effect 601–2  
 respiratory acidosis/alkalosis effect 599–601

- cerebral oxygenation 497  
 correlation with outcome 502–3
- cerebral palsy (CP) 3, 19–21, 525–6  
 asphyxia relationship 3, 129, 411, 835–7  
 chorioamnionitis association 307–9  
 incidence 19–21, 239, 307  
 IUGR association 162–3  
 meconium-stained amniotic fluid association 614–15  
 pathophysiologic mechanisms 619  
 prematurity and 308  
 risk factors 19–21, 307–8
- cerebrospinal fluid (CSF)  
 congenital syphilis diagnosis 364, 365  
 laboratory evaluations 413  
 meningitis diagnosis 338–9
- cervical incompetence, preterm birth and 130–1
- cesarean delivery  
 preterm fetus 134–5  
 malpresentations 134–5  
 multiple gestation 135  
*see also* vaginal birth after previous cesarean section (VBAC)
- Chiari II malformation 118–19
- chickenpox 366
- chorangiomas 523
- chorioamnionitis 303–10, 522, 525–6, 527–8  
 clinical manifestations 303  
 fetal outcome 306–9  
 cerebral palsy 307–9  
 neonatal asphyxia 307  
 hyperthermia and 103  
 incidence 304–5  
 laboratory investigation 303–4  
 maternal outcome 306  
 meconium passage association 618  
 microbiologic pathogens 305–6  
 premature rupture of membranes and 131  
 risk factors 304  
 treatment 309–10  
 ultrasonographic imaging 304
- chorioretinitis, congenital toxoplasmosis and 356
- choroid plexus 447  
 hemorrhage 470
- chromosomal abnormalities, IUGR and 148
- chronic lung disease (CLD) 643–5, 653, 655  
 following extracorporeal membrane oxygenation 648, 650, 651
- cigarette smoking *see* smoking during pregnancy
- circulatory arrest, in cardiac surgery 664–5  
*see also* deep hypothermic circulatory arrest (DHCA)
- Citrobacter diversus*, neonatal meningitis 336, 340, 343
- clonic seizures 738–9  
 multifocal (fragmentary) 739
- cocaine abuse 282–6  
 cocaine in breast milk 286  
 necrotizing enterocolitis and 284, 805  
 teratogenic effects 283–5
- cognitive ability, asphyxia outcomes  
 early childhood 837–8  
 long-term outcome 843–4
- Collaborative Perinatal Study (CPS) 523–6
- colloid solutions 686–7
- computed tomography (CT) 414, 446, 471–2  
 hypoxic-ischemic injury 479–83  
 timing of asphyxia 546
- congenital adrenal hyperplasia (CAH) 196–7
- congenital aneurysms 122
- congenital diaphragmatic hernia (CDP) 652
- congenital heart disease 664, 703–4  
*see also* cardiac surgery
- congenital hypopituitarism 560–1
- congenital optic nerve hypoplasia (CONH) 560–1
- congenital syphilis *see* syphilis
- contraction stress test (CST) 214–15  
 interpretation 215
- corticosteroids  
 antenatal, intracranial hemorrhage prevention 185
- cerebral edema management 705–6  
 necrotizing enterocolitis and 805–6  
 neonatal meningitis treatment 344–5
- counseling, with prior cesarean section 249
- craniorachischisis 112
- creatinase brain isoenzyme (CK-BB) 413, 544–5
- crystalloid solutions 686–7
- Cushing's disease 196
- cytokines  
 cerebral palsy and 308, 309, 527  
 neonatal meningitis and 337  
 placental pathology and 526–7  
 preeclampsia and 527
- cytomegalovirus (CMV), congenital 358–60  
 outcome 358–60  
 infants asymptomatic at birth 358–9  
 infants symptomatic at birth 359–60  
 recommendations 360
- damages 875–6
- Dandy-Walker malformations 119
- debrancher enzyme deficiency 405
- decompression, abdominal 163–5
- deep gray nuclei lesions 417–18
- deep hypothermic circulatory arrest (DHCA) 663  
 in cardiac surgery 664–6  
 circulatory arrest 664–5  
 hypothermia 665–6  
 near-infrared spectroscopy (NIRS) applications 503–5  
 reperfusion injury 666–7
- defibrillation, neonatal resuscitation 685
- delivery complications 129, 135–7  
 preterm delivery management 132–7  
 fetal monitoring 134  
 malpresentation 134–5

## 892 Index

- delivery complications (*cont.*)  
   preterm delivery management (*cont.*)  
     multiple gestations 134–5  
     route of delivery 134–5  
 demyelination 721  
 depression, maternal 198–9  
 diabetes mellitus, maternal 191, 192–4  
   gestational diabetes 194  
   type I 192–4  
   type II 194  
 diabetic ketoacidosis 192  
 Diamond–Blackfan anemia 202  
 dietary supplementation, IUGR and 149–50, 165  
 diffuse optical tomography (DOT) 509  
 diffusion-weighted imaging (DWI) 446, 479  
 disseminated intravascular coagulation (DIC) 247  
 diuretic therapy, pulmonary parenchymal disease 701  
 dobutamine, cardiac output maintenance 697  
 documentation 876–80  
 dopamine, cardiac output maintenance 696  
 Doppler ultrasound  
   cerebral blood flow studies 448–9  
   effects of therapies 449  
   pulsatility index (PI) 449  
   resistive index (RI) 448–9  
   fetal well-being assessment 221–2  
 drug abuse *see* substance abuse  
 ductal patency 455, 702  
 ductal shunting, detection of 698–700  
 duty of care 873–4  
   breach of 874–5  
 dystonia 748  
  
 early infantile epileptic encephalopathy 772  
 early myoclonic encephalopathy 772  
 edema  
   cerebral 415, 481, 545  
     computed tomography 463  
     management 704–6  
   hydrops 586–8  
     *see also* hydrops fetalis  
 electroclinical dissociation (ECD) 752–6  
 electroencephalography (EEG) 413–14, 425–42  
   asphyxia timing 543  
   in diffuse encephalopathy 436–40  
     grading of encephalopathy 437–8  
     prognostic value of encephalopathic EEG 438–40  
   specificity of encephalopathic EEG 438–9  
   in specific disorders 440–2  
     Aicardi syndrome 440  
     encephalitis 442  
     holoprosencephaly 441  
     hyperammonemia 441  
     intraventricular hemorrhage 441  
     lissencephaly 440  
     maple syrup urine disease 441  
     maternal drug abuse 442  
     meningitis 442  
     nonketotic hyperglycemia 441  
     periventricular leukomalacia 441–2  
     pyridoxine dependency 441  
     stroke 442  
   indication for 425–6  
   maturational features 430–6  
     delta brush pattern 431  
     discontinuity of the background 431  
     midline rhythms 436  
     ontogeny of sleep stage 430  
     sharp waves 431  
     theta burst pattern 431  
   seizures and 425–6, 429, 736  
     brief rhythmic discharges 751  
     ictal EEG patterns 749–50  
     interictal EEG patterns 756–60  
     periodic discharges 750–1  
     seizure criteria 748–51  
     seizure duration and topography 750  
   serial EEGs 426  
   technical considerations 426–30  
     age of infant 428  
     artifacts 428  
     documenting behavior during recording 428–9  
     duration to obtain sleep states 427–8  
     electrodes and application 426–7  
     interpretation 429–30  
     report format 429–30  
     sedation 427  
     seizures 429  
     working in challenging environment 428  
   timing of 426  
   value of 425  
 electronic fetal monitoring (EFM) 135, 505–6  
   early studies 227  
   history of 226–7  
   preterm labor 134, 135–7  
   role in perinatal asphyxia prediction 237–40  
   *see also* fetal heart rate; fetal well-being assessment  
 embryonic development 111, 112  
   *see also* maturation  
 EMTALA (Emergency Treatment and Active Labor Act 1986) 860  
 encephalitis  
   EEG recordings 442  
   herpes simplex virus 369, 370  
   varicella-zoster syndrome 368  
 encephalocele 114, 123  
   anterior 115–16  
   basal 115–16  
   occipital 114–15

- sincipital 115–16
- encephalopathy 14–16, 83
- chronology of 534–5
  - conditions causing 18
  - early infantile epileptic encephalopathy 772
  - early myoclonic encephalopathy 772
  - EEG applications 436–40
    - grading of encephalopathy 437–8
    - prognostic value of encephalopathic EEG 439–40
    - specificity of encephalopathic EEG 438–9
  - HIV 383–4
  - see also* hypoxic–ischemic encephalopathy (HIE)
- enteral feeding 791–5
- gastric feeding 791–3
  - guidelines 795, 809
  - late introduction of 809
  - necrotizing enterocolitis and 705, 800–2
    - rate and volume of feeds 802
    - timing of feeding 800–2
  - route of 809
  - slow advancement of 809
  - transpyloric feeding 793–5
- enterococcal group D streptococci 327
- ependymitis 451
- epidermal growth factor (EGF), necrotizing enterocolitis and 806–7
- epidural anesthesia 134
- epilepsy
- asphyxia outcomes 838–9
  - maternal 197–8
  - progressive neonatal epileptic syndromes 772–3
  - see also* seizures
- epinephrine
- neonatal cardiac output enhancement 685
  - neonatal cardiac output maintenance 697
- Erb's palsy, shoulder dystocia and 266
- erythroblastosis fetalis 201
- erythropoietin overproduction, IUGR and 156
- Escherichia coli* 325–6
- chorioamnionitis 305
  - neonatal meningitis 335–6
  - neonatal sepsis 315, 325–6
- etamsylate, intracranial hemorrhage prevention 184
- ethanol abuse *see* alcohol abuse
- exchange transfusion
- hyperbilirubinemia management 575
  - polycythemia therapy 582
- excitatory neurotransmitters
- neurotoxicity 61–5
    - animal model 36–7, 47
  - receptor inhibitors 707–8
- exogenous surfactant
- hemodynamic effects 500–1
  - in extended neonatal management 694–5
  - persistent pulmonary hypertension of the newborn treatment 641
- extended management 692–710
- anemia management 697–8
  - barbiturates 706–7
  - calcium-channel blockers 708
  - cerebral edema 704–6
    - corticosteroids 705–6
    - hyperventilation 704–5
    - mannitol 706
  - consultation 710
  - cyanotic congenital heart disease 703–4
  - detection of ductal shunting 698–700
  - excitatory amino acid receptor inhibitors 707–8
  - growth factors 709–10
  - hyperoxia test 698
  - hyperoxia–hyperventilation test 700–1
  - hypothermia 709–10
  - hypoxemia management 698
  - monosialogangliosides 709
  - oxygen free radical inhibitors 708–9
  - pulmonary arterial disease 703
  - pulmonary parenchymal disease 701–3
  - referral 710
  - supporting ventilation 692–5
  - sustaining cardiac output 695–7
    - afterload reduction 697
    - inotropic drugs 696–7
- extracorporeal membrane oxygenation (ECMO) 440
- hemodynamic effects 500
  - hydrops fetalis 590
  - in extended neonatal management 695
  - intracranial hemorrhage 176–7
  - meconium aspiration syndrome 621–3
  - outcomes 621–3, 649
    - vs conventional medical therapy 652–3
    - with congenital diaphragmatic hernia 652
  - persistent pulmonary hypertension of the newborn treatment
    - 642–3, 647–55
    - follow-up studies 648–52
    - risks associated with 647–8
- Fanconi's anemia 202
- fatty acid oxidation defects 260–1, 401–2
- Federal Rehabilitation Act (1973) 866
- femur length (FL) 153
- fetal alcohol syndrome (FAS) 200, 277–9
- fetal blood sampling, scalp 240–1
- fetal breathing movements (FBMs), hypoxia response 87–8
- fetal deformation syndrome 131
- fetal disruption sequence 283–4
- fetal distress 240
- meconium-stained amniotic fluid and 613–14
  - misuse of term 876–9
- fetal growth
- affecting factors 146–7

## 894 Index

- fetal growth (*cont.*)  
 affecting factors (*cont.*)  
   fetal growth factors 147  
   placental growth factors  
 disproportional 146  
 proportional 146  
*see also* intrauterine growth retardation (IUGR); maternal conditions affecting fetal development
- fetal growth retardation *see* intrauterine growth retardation
- fetal heart rate (FHR) 135–6, 231–7  
 accelerations 231–2  
 asphyxia/hypoxia and 92, 94, 104–5, 232–3  
   timing of 542, 627  
 baseline rate 231  
 bradycardia 89–90, 104–5, 218, 234–7  
 monitoring 135–7, 216, 226, 542  
 patterns 226–7  
   episodic decelerations 234  
   management of 137–8  
   sinusoidal patterns 237  
 periodic patterns 136–7, 233–4, 240  
   early decelerations 233, 234  
   late decelerations 233–4, 235  
   variable decelerations 233, 234  
 physiology of 227–31  
   cardiac output regulation 228–31  
   fetal oxygenation 227–8  
   role of autonomic nervous system 228  
 tachycardia 136, 234  
 variability 136, 231  
   absent/minimal variability 237  
*see also* electronic fetal monitoring (EFM)
- fetal hydantoin syndrome 198
- fetal monitoring *see* electronic fetal monitoring; fetal well-being assessment
- fetal movement  
 breathing movements (FBMs), hypoxia response 87–8  
 cessation of 541, 627  
 maternal perception of 219–20, 627  
 writhing movements 541
- fetal pulse oximetry 506
- fetal weight determination 132
- fetal well-being assessment 153–4, 212–22  
 biophysical profile (BPP) 153, 220–1  
 contraction stress test (CST) 214–15  
 Doppler ultrasound 221–2  
 fetal neurologic state 214  
 maternal perception of fetal movement 219–20  
 nonstress test (NST) 216–18  
 screening test characteristics 213–14  
 vibroacoustic stimulation (VAS) 218–19  
*see also* electronic fetal monitoring (EFM)
- fluid attenuation inversion recovery technique (FLAIR) 472, 473
- fluid resuscitation 685–7  
 crystalloid and colloid solutions 686–7
- focal brain injury 17–18, 419–20
- folinic acid-responsive seizures 399
- fontanels 447
- forceps deliveries 138, 139, 140, 267–9
- fragile X syndrome 202
- fragmentary clonic seizures 739
- free radicals 68–9  
 inhibitors 708–9
- fructose 1,6-bisphosphatase deficiency 405
- fumaric aciduria 401
- furosemide, pulmonary parenchymal disease 701–2
- GABA, neuroprotective role 718
- GABA transaminase deficiency 399–400
- GAMT deficiency 400
- Gardnerella vaginalis*, chorioamnionitis 305
- gastric feeding 791–3
- gastroesophageal reflux (GER) 652, 791
- gastrointestinal tract development 791, 792–3  
 complications in premature infants 794
- genetic disorders, maternal 201–2
- genital herpes 369, 371  
*see also* herpes simplex virus
- germinal matrix hemorrhage (GMH) 177, 178  
 diagnosis 180  
 neurosonography 449–55
- gestational age determination 132  
 importance for EEG interpretation 428
- gestational diabetes 192, 194
- gluconeogenesis 566–7  
 disorders 405
- glucose, hypoglycemia correction 681–2  
*see also* hyperglycemia; hypoglycemia
- GLUT-1 deficiency syndrome 400
- glutamate 32, 36, 61–5  
 excitotoxicity 36–7, 63–5
- glutamate receptors (GluRs) 32–6, 62, 64  
 classification 35  
 role in brain damage  
   animal model 32–7  
   excitotoxic mechanisms 36–7
- glutamate transporters 36  
 defects, animal model 37–41, 43
- glutaric aciduria 403
- glycine-proline-glutamate (GPE), neuroprotective role 722
- glycogen storage disorders 405
- glycogen synthetase deficiency 405
- glycolysis 59, 85
- Graves disease 195
- gray matter injury, maturation effects 100–1
- group A streptococcus  
 chorioamnionitis 305  
 neonatal sepsis 315, 326



- group B streptococcus (GBS) 320  
 chorioamnionitis 305  
 neonatal meningitis 335–6, 340  
 outcome 345–7  
 neonatal sepsis 315, 320–5  
 clinical presentation 321  
 diagnosis 322  
 epidemiology 320  
 outcome 322  
 pathogenesis 321  
 prevention 322–5, 347–8  
 risk factors 321  
 treatment 322  
 vaccination 325
- group D streptococci 327
- growth  
 asphyxia outcomes 841  
 following IUGR 161  
*see also* fetal growth; intrauterine growth retardation (IUGR)
- growth factors  
 extended neonatal management 709–10  
 fetal 147  
 necrotizing enterocolitis and 806–7  
 neuroprotective role 723  
 placental 147  
*see also* insulin-like growth factors (IGFs)
- growth hormone (GH) 147
- Haemophilus influenzae*, neonatal meningitis 336, 344
- hair, fetal 293  
 use in drug screening 293
- hashish 281
- hashish oil 281
- hearing loss 621, 622  
 asphyxia outcomes 839–40  
 following congenital infection  
 cytomegalovirus 358–9  
 toxoplasmosis 356  
 following persistent pulmonary hypertension of the newborn  
 646–7
- heart surgery *see* cardiac surgery
- HELLP syndrome 258–61  
 definition 258–9  
 epidemiology 259  
 neonatal outcome 259–60  
 delivery 259  
 outcome studies 259–60  
 pathophysiology 259  
 fetal–maternal interaction 260–1
- hemangioblastoma 122
- hematocrit, increased  
 effects on organ blood flow and function 578–80  
 IUGR association 156–7  
*see also* polycythemia
- hematologic disease, maternal 201
- hemodynamics  
 near-infrared spectroscopy (NIRS) 494, 495–7  
 during intensive care 498–502  
*see also* cerebral blood flow (CBF); cerebral blood volume (CBV)
- hemorrhage  
 computed tomography 472  
 placenta previa and 245  
 pulmonary, IUGR association 157  
 ultrasonography 447, 449–55  
*see also* intracranial hemorrhage; intraventricular hemorrhage
- hemorrhagic endovasculopathy (endovasculitis) 523
- heroin 286–7
- herpes simplex virus (HSV) 368–72  
 diagnosis 371  
 disseminated disease 370, 371–2  
 intrauterine infection 370  
 manifestations and consequences 369–71  
 recommendations 371  
 transmission to the fetus and newborn 369  
 treatment 371–2
- herpes zoster virus 368  
*see also* varicella-zoster virus
- HHH syndrome 404
- high-frequency ventilation (HFV) 641, 693–4
- HIV *see* human immunodeficiency virus
- holoacrania 112
- holocarboxylase synthetase deficiency 403
- holoprosencephaly 116, 768  
 EEG recordings 441
- human immunodeficiency virus (HIV) 377–86  
 perinatal infection  
 antiretroviral therapy 385, 386  
 diagnosis 381, 384  
 neurologic manifestations 383–5  
 prognostic factors 385–6  
 survival 386  
 time to AIDS 382–3  
 perinatal transmission 378–82  
 breast milk 381  
 prevalence of maternal HIV 382  
 recommendations 386  
 transfusion-acquired infection 382  
 risk of 382
- hydranencephaly 120
- hydrocephalus 117–18  
 associated conditions 118–19  
 Chiari II malformation 118–19  
 Dandy–Walker malformation 119  
 neonatal meningitis 341  
 diagnosis 449
- hydrops fetalis 586–91  
 antenatal management 589  
 immune hydrops 586

## 896 Index

- hydrops fetalis (*cont.*)  
   mechanisms of edema formation 586–8  
   neurologic injury 588  
   nonimmune hydrops 586  
     associated conditions 586, 587  
   outcome 590–1  
   perinatal management 589  
   postnatal diagnostic studies 589  
   postnatal management 589–90  
 3-hydroxyisobutyric aciduria 403  
 hyperammonemia 404–5  
   EEG recordings 441  
 hyperbilirubinemia  
   bilirubin neurotoxicity 571–3  
   management of 574–5  
   prediction of 573–4  
 hypercapnia  
   cerebral blood flow responses 593–5  
   cerebral metabolism responses 599–600  
 hyperekplexia 748  
 hyperglycemia 192–3, 194  
   ischemic neuronal injury and 602–3  
   IUGR association 155  
 hyperinsulinemia 192  
   hyperinsulinemic hypoglycemia 561–3  
   transient 559  
 hypernatremia, seizure etiology 765  
 hyperoxia test 698  
 hyperoxia–hyperventilation test 700–1  
 hypertension during pregnancy 256  
   *see also* HELLP syndrome; preeclampsia  
 hyperthermia  
   following deep hypothermic circulatory arrest 666–7  
   hypoxic–ischemic brain injury and 102–3, 723, 724  
 hyperthyroidism, maternal 195  
 hyperventilation 621, 640, 644, 693  
   cerebral blood flow and 640, 644  
   cerebral edema management 704–5  
   follow-up studies 644–6  
 hyperviscosity 578, 579, 637  
   polycythemia relationship 579  
 hypoalbuminemia 588  
 hypocalcemia  
   IUGR association 156  
   seizure etiology 764–5  
   treatment 775  
 hypocapnia  
   cerebral blood flow responses 595–7  
   cerebral metabolism responses 600–1  
   ventilator management 640  
 hypoglycemia, neonatal 193, 553–68, 681  
   blood glucose measurement 556  
   clinical manifestations 556  
   definition 554–6  
   follow-up studies 564–6  
   hormone deficiencies 560–1  
   hyperinsulinemic (organic) hypoglycemia 561–3  
     transient hyperinsulinemia 559  
   IUGR association 155  
   management 556–7  
   pathogenesis/pathophysiology 566–7  
   prognosis 563  
     animal studies 563–4  
   recurrent/persistent neonatal hypoglycemia 559–60  
   seizure etiology 764  
   therapy 557–9, 775  
     failure to respond 559  
     resuscitation and 681–2  
 hyponatremia, seizure etiology 765  
 hypopituitarism, congenital 560–1  
 hypotension, fetal asphyxia and 90–1, 93, 105  
   role in neuronal injury 98–9, 392–3  
 hypothermia  
   extended neonatal management 709–10  
   in cardiac surgery 665–6  
   infection susceptibility and 157  
   IUGR association 156  
   neuroprotective effect 102, 415, 723–5  
     in resuscitation/reperfusion 724  
     prolonged cooling 724–5  
     window of opportunity for other therapies 725, 726–7  
   *see also* deep hypothermic circulatory arrest (DHCA)  
 hypothyroidism, maternal 194–5  
   IUGR association 157–8  
 hypotonia 545, 764  
 hypovolemia 686  
 hypoxemia 698  
 hypoxia 83, 102  
   fetal adaptations 86  
   fetal responses to 86–8, 232–3  
     maturational changes 88  
     prolonged hypoxia 88  
   necrotizing enterocolitis etiology 804–5  
   pathogenesis of cell death 84–5  
   *see also* asphyxia  
 hypoxic–ischemic encephalopathy (HIE) 4, 58–76, 830–1  
   acidosis relationship 602–7  
     metabolic acidosis 602–4  
     respiratory acidosis 604–6  
   assessment of 411–14  
     EEG 413–14  
     general evaluation 411  
     laboratory evaluations 413  
     neuroimaging 414, 457–9, 474–5, 479–84  
     neurologic assessment 412–13  
   categories of 834  
   cellular/molecular biology of  
     cellular energy transformations 58–61

- excitatory neurotransmitter neurotoxicity 61–5
- intracellular calcium overload 65–8
- iron 70
- necrosis vs apoptosis 72–6
- nitric oxide 70–2
- reactive oxygen species 68–9
- chronology of 534–5
- clinical features 396–7, 411–14
- management 414–16
  - neuroprotection 415–16
  - see also* extended management
- patterns of brain injury 392–6, 416–21
  - brainstem 418
  - cerebellum 418–19
  - deep gray nuclei 417–18
  - focal brain injury 419–20
  - parasagittal border-zone injury 416–17
  - periventricular/intraventricular hemorrhage 421
  - white-matter injury 420–1
- seizure etiology 762–3
- severity of 412–13
  - staging system 833, 834
- see also* animal models; asphyxia; encephalopathy; neuronal degeneration; neuroprotective mechanisms after hypoxic–ischemic injury
- immune hydrops 586
- inborn errors of metabolism 392–7, 398, 405–6
  - clinical features 396–7
  - patterns of brain injury 392–6
  - seizure etiology 770–2
  - see also specific conditions*
- incontinentia pigmenti 772–3
- indometacin
  - hemodynamic effects 499–500
  - intracranial hemorrhage prevention 184
- infant behavior, IUGR and 159
- infarction 72, 520
  - brain 17–18, 392, 416–17, 419–20
    - seizure etiology 765–8
  - neonatal meningitis and 341
  - periventricular hemorrhagic venous infarction (PHVI) 451, 455–7
  - ultrasonography 468
- infections
  - congenital 355
    - seizure etiology 768
  - maternal 355
    - IUGR association 148
    - necrotizing enterocolitis and 805
    - susceptibility to, IUGR association 157
    - see also* sepsis, neonatal; *specific infections*
- iniencephaly apertus 114–15
- inotropic drugs
  - neonatal extended management 696–7
  - dobutamine 697
  - dopamine 696
  - epinephrine 697
- neonatal resuscitation 687–8
  - calcium 687–8
- instrumental deliveries 139, 267–70
  - see also* operative vaginal delivery
- insulin 147, 161
- insulin resistance 163
- insulin-like growth factors (IGFs) 147
  - neuroprotective role 719–22
    - induction of 720–1
    - neuronal rescue 721
    - white-matter injury and 721–2
- intelligence quotient (IQ)
  - asphyxia outcomes 837–8, 843–4
  - IUGR and 159–60, 161–2, 163
  - maternal diabetes association 193
  - maternal thyroid disease and 195
- intensive care, appropriateness issues 859–71
  - cost of care disproportional to hoped-for benefits 867–9
  - infant with virtually no chance of survival 862–3
  - infant's quality of life following intervention 865–7
  - intervention harms disproportional to hoped-for benefits 863–5
  - see also* extended management
- intestinal trefoil (ITF) 806
- intracranial hemorrhage (ICH) 175–85
  - arteriovenous malformations 176
  - classification 449–51
  - complications 181
    - posthemorrhagic ventriculomegaly (PHVM) 181–2
  - diagnosis 180–1
  - extracorporeal membrane oxygenation (ECMO) and 176–7
  - full-term infant 175–7
  - germinal matrix hemorrhage (GMH) 177, 178, 180, 449–55
  - imaging
    - magnetic resonance imaging 476
    - near-infrared spectroscopy 507–8
    - neurosonography 449–55
  - incidence 179, 449
  - instrumental delivery and 268
  - intraparenchymal hemorrhage (IPH) 177–8
  - neonatal alloimmune thrombocytopenia and 176
  - outcome 182–3
  - pathogenesis 178–9
  - periventricular hemorrhage 421
    - seizure etiology 765
  - preterm infants 177–8
    - periventricular leukomalacia 178
  - prevention 183–5
    - antenatal prevention 184–5
    - antenatal steroids 185
    - etamsylate 184
    - indometacin 184

## 898 Index

- intracranial hemorrhage (ICH) (*cont.*)  
 prevention (*cont.*)  
   pancuronium 184  
   phenobarbital 183–4, 185  
   preterm infant 183–4  
   tranexamic acid 184  
   vitamin E 184  
   vitamin K 185  
 protective factors 179–80  
 risk factors 179–80, 449  
 subdural 175  
*see also* hemorrhage; intraventricular hemorrhage
- intraparenchymal hemorrhage (IPH) 177–8  
 neurosonography 451, 458, 465, 466–7  
 outcome 182
- intrauterine growth retardation (IUGR) 145–66  
 associated problems 154–8  
   delayed ossification 157–8  
   fetal/neonatal asphyxia 154–5  
   hematologic problems 156–7  
   hyperglycemia 155  
   hypocalcemia 156  
   hypoglycemia 155  
   hypothermia 156  
   necrotizing enterocolitis 157  
   pulmonary hemorrhage 157  
   susceptibility to infection 157  
 asymmetrical 146  
 brain sparing 146  
 detection of 153–4  
 etiology 148–53  
   environmental factors 151–2  
   fetal factors 148–9  
   maternal factors 149–51  
   placental factors 149  
   smoking during pregnancy 151, 152, 279–80  
 hypoxic–ischemic brain injury risk and 102  
 incidence 147–8  
 multiple gestation relationship 149  
 neurobehavioral abnormalities 158–9  
   accelerated neurological development 158  
   altered behavior 159  
   parental interaction 159  
 outcome 159–63  
   cerebral palsy 162–3  
   development 161  
   follow-up 162  
   in adult life 163  
   IQ 161–2  
   learning deficits 163  
   morbidity 160–1  
   mortality 160–1  
   physical growth 161  
 prevention 163–5  
 symmetrical 146  
*see also* fetal growth
- intraventricular hemorrhage (IVH) 102, 416, 421  
 cerebral blood flow correlation 502  
 diagnosis 180  
 EEG recordings 441  
 full-term infant 175–6  
 management 176  
 neurosonography 449–55  
 outcome 182, 183  
 predisposing factors 176  
 preterm infant 177–8  
 seizure etiology 765  
*see also* hemorrhage; intracranial hemorrhage
- iron toxicity 70
- ischemia 85  
 computed tomography 462  
 necrotizing enterocolitis etiology 804–5  
 ultrasonography 447, 464  
*see also* hypoxic–ischemic encephalopathy (HIE)
- isoproterenol, neonatal cardiac output enhancement 685
- isovaleric acidemia (IVA) 403
- jaundice *see* hyperbilirubinemia
- jitteriness 743–6
- kernicterus 571  
 reemergence of 575–67  
*see also* hyperbilirubinemia
- ketoacidosis 403
- ketonemia, maternal 193–4
- labor complications 129, 135–7  
 preterm labor management 131–7  
   fetal monitoring 134  
   malpresentation 134–5  
   multiple gestations 134–5  
   route of delivery 134–5  
 pyrexia 103  
 uterine rupture 250
- lactic acid dehydrogenase (LDH) 545
- lactic acidosis 401–3, 602–3
- language skills, asphyxia outcomes 847–8
- lazaroids 709
- learning deficits, IUGR association 163
- legal issues *see* medicolegal issues
- leptin 147
- leukocytosis, in chorioamnionitis 303
- life expectancy, asphyxia outcomes 851
- Lindau syndrome 122, 202
- lipoamide dehydrogenase deficiency 401
- liquid ventilation 643
- lissencephaly 768  
 EEG recordings 440
- Listeria monocytogenes*  
 chorioamnionitis 305

- neonatal meningitis 335–6
- long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD) deficiency 260–1, 401–2
- LSD abuse 290
- lumbar puncture, neonatal bacterial meningitis and 333–5
- lung maturation
  - IUGR and 158
  - maternal diabetes association 193
- lymphocytes, timing of asphyxia and 534, 543
- lymphocytic interstitial pneumonitis (LIP) 386
- lysine protein intolerance 405
  
- macrencephaly 119
- macrosomia
  - maternal diabetes and 193, 194
  - shoulder dystocia and 264–5
- magnesium sulfate 708
- magnetic resonance imaging (MRI) 414, 446, 472–9
  - asphyxia 465
  - diffusion-weighted imaging (DWI) 472, 479
  - fluid attenuation inversion recovery technique (FLAIR) 472, 473
  - functional MRI (fMRI) 478
  - gradient recalled echo (GRE) 475
  - hypoxic–ischemic injury 479–83
  - magnetization transfer imaging (MTI) 472, 473–6
  - MR angiography (MRA) 472, 475
  - MR spectroscopy (MRS) 472, 476–7
  - perfusion MRI (PMRI) 472, 477–8
  - suppression short T1 inversion recovery imaging (STIR) 472, 473
  - timing of asphyxia 546–7
- magnetic resonance (MR) proton spectroscopy 446
- malformations 111
  - antidepressant medication association 199
  - brain 111, 120–3
    - seizure etiology 768–70
  - diagnostic approach 123–4
  - IUGR and 148
  - maternal diabetes association 192, 194
  - timing of 111
  - vascular 120–3
  - see also specific malformations*
- malnutrition
  - fetal, effect on adult life 163
  - maternal 191–2
    - IUGR and 149–50, 165
- malpresentation, preterm fetus 134–5
- mannitol, cerebral edema management 706
- maple syrup urine disease (MSUD) 403–4
  - EEG recordings 441
- marijuana abuse 281–2
- maternal conditions affecting fetal development 191–207
  - adrenal disorders 196–7
    - congenital adrenal hyperplasia 196–7
  - autoimmune disorders 202–6
  - diabetes mellitus 192–4
  - genetic disorders 201–2
  - hematologic disease 201
  - infections, IUGR association 148
  - malnutrition 191–2
    - IUGR association 149–50, 165
  - metabolic disorder reproductive effects 200–1
  - migraine headache 198
  - psychiatric disorders 198–200
  - seizure disorder 197–8
  - thyroid disease 194–6
- maturation
  - fetal responses to asphyxia and 93–6
  - fetal responses to hypoxia and 88
  - hypoxic–ischemic brain injury relationship 100–2
  - lung
    - IUGR and 158
    - maternal diabetes association 193
  - neurological, acceleration in IUGR 158
- mean arterial blood pressure (MABP) 498, 499, 503
- mechanical ventilation *see* ventilation
- Meckel syndrome 115
- meconium 9, 293, 525–6, 528–31
  - enigmatic causes of meconium-induced effects 531
  - historical considerations 528
  - midtrimester fetuses and 529
  - pathophysiology of meconium passage 617–18
  - pharmacopathologic concepts of 529–30
  - thick-versus-thin consistency 629–30
  - timing of meconium passage 623–6
  - use in drug screening 293
  - see also* meconium aspiration syndrome; meconium staining
- meconium aspiration syndrome (MAS) 529, 530–1, 612–13, 614
  - mechanisms of neurologic injury 620–3
  - pulmonary pathology and 528–9
  - see also* meconium
- meconium staining 522, 528
  - meconium-stained amniotic fluid (MSAF) 612–17
    - fetal distress and 613–14
    - mechanisms of neurologic injury 618–23
    - neonatal resuscitation 679–80
    - neurologic adverse outcomes 614–17
    - nonneurologic adverse outcomes 614
    - timing of asphyxia 542–3
  - seizure etiology 763–4
  - timing of meconium passage 623–6
  - see also* meconium
- medical error 785
- medical training
  - future prospects 788–9
  - historical perspective 785–6
  - new methodologies 786–8
- medicolegal issues 873–85
  - case studies 880–5
  - causation 875
  - damages 875–6

## 900 Index

- medicolegal issues (*cont.*)  
   documentation 876–80  
   duty 873–4  
     breach of 874–5  
 medium-chain acyl CoA dehydrogenase (MCAD) deficiency 401  
 megalencephaly 119–21  
 memory, asphyxia outcomes 848–9  
 meningitis, neonatal 333–48  
   antibody to common bacteria 340  
   complications 340–1  
   diagnosis 338–40  
     cerebrospinal fluid 338–9  
     clinical features 338  
     imaging studies 340  
     laboratory evaluations 339–40  
   EEG recordings 442  
   etiology 335–6  
   incidence 333  
   lumbar puncture 333–5  
   outcome 345–7  
     mortality 335, 345  
     neurologic sequelae 345–7  
   pathology 336–8  
     anatomical pathology 337  
     bacteremia and 336–7  
     blood–brain barrier 337–8  
     cytokines 337  
   prevention 347–8  
     maternal approach 348  
     neonatal approach 347  
   treatment 341–5  
     choice of antibiotics 342–3  
     corticosteroids 344–5  
     duration of antibiotics 343–4  
 meningoencephalitis  
   herpes simplex virus 370  
   rubella 361  
 meningomyelocele 113  
   Chiari II malformation association 118–19  
 mental retardation 3  
   asphyxia outcomes 837–8  
   definition 21  
   epidemiology 21–2  
 mercury toxicity 152  
 meroacrania 112, 123  
 metabolic disorders, reproductive effects of 200–1  
 metabolic status, hypoxic–ischemic brain injury risk and 102  
 metabotropic glutamate receptors (mGluRs) 776  
 methadone 286, 287–8  
   in breast milk 287–8  
 methamphetamine abuse 288–9  
 methylmalonic acidemia (MMA) 403  
 methylprednisone 709  
 mevalonic aciduria 400, 404  
 microcephaly 117, 123, 124, 840  
   asphyxia outcomes 840  
   with congenital toxoplasmosis 356  
   with rubella infection 361–2  
 migraine headache 198  
 mitochondrial disorders 400, 402–3  
 monosialgangliosides 709  
 mortality 8  
   asphyxia and 8  
   IUGR and 160–1  
   neonatal bacterial meningitis 335, 345  
   neonatal sepsis 319  
   perinatal mortality rate (PMR) 212–13  
 motilin 618  
 motor skills, asphyxia outcomes 841–3  
 multifocal clonic seizures 739  
 multiple acyl CoA dehydrogenase deficiency (MADD) 403  
 multiple carboxylase deficiency (MCD) 403  
 multiple gestation  
   IUGR relationship 149  
   preterm birth and 130  
     delivery management 135  
   twin-to-twin transfusion syndrome, anemia and 157  
 multiple organ dysfunction 16–17  
*Mycoplasma hominis*, chorioamnionitis 305  
 myelocele 113  
 myocardium  
   dysfunction in hydrops fetalis 588  
   injury during asphyxia 91  
 myoclonic seizures 740–3  
 myoclonus without EEG seizures 746–8  
  
*N*-methyl-D-aspartate (NMDA) receptors 35  
   antagonists 707–8  
   phosphorylation, animal model 41–5  
   striatal neurodegeneration and 41–5  
 Na,K-ATPase defects, striatal neurodegeneration and 45–8  
 naloxone 287  
   neonatal resuscitation and 683  
 nasogastric (NG) feeding 791–3  
 nasojejunal (NJ) feeding 793–4  
 near-infrared spectroscopy (NIRS) 490–512  
   applications 495–506  
     antenatal applications 505–6  
     cardiovascular surgery 503–5  
     cerebral hemodynamic parameter measurement 494, 495–7, 498–502  
     cerebral oxygenation parameter measurement 497–502  
     correlation with outcome 502–3  
     during intensive care 498–502  
   brain imaging 507–11  
     exogenous dyes and contrast agents 510–11  
   devices 490–3  
   future challenges 511–12  
   limitations 494–5  
 necrosis 48–51, 72–5, 716–17

- apoptosis–necrosis continuum 51–3  
 pontosubicular 418  
*see also* cell death; neuronal degeneration
- necrotizing enterocolitis 157, 798–808  
 clinical picture 798–9  
 epidemiology 798  
 outcome 808  
 pathogenesis 800–8  
   breast milk benefits 803–4, 808, 809  
   cocaine exposure 284, 805  
   corticosteroid role 805–6  
   enteral feeding 795, 800–2  
   immunologic considerations 803  
   infectious agents 805  
   ischemia and hypoxia 804–5  
   osmolality of feeds 802–3  
   vitamin E role 805
- prevention 808  
 staging 800, 801  
 treatment 800
- Neisseria meningitidis* 336
- neonatal alloimmune thrombocytopenia 176
- Neonatal Medical Index (NMI) 821–4
- neonatal neurologic syndrome 14–16
- neonatal resuscitation 673–89  
 airway clearing 677–8  
 anticipation of the need for 674–5  
 cardiac output enhancement 680, 684–8  
   atropine 685  
   cardioversion and defibrillation 685  
   epinephrine 685  
   fluid resuscitation 685–687–688  
   inotropic drugs 687  
   isoproterenol 685
- delivery room decision making 688–9
- drug administration routes 680–1
- following meconium staining of the amniotic fluid 679–80
- objectives of 673–4
- positioning of infant 678–9
- preparation 675–7  
 equipment 676, 677  
 immediate assessment 676–7  
 personnel 675–6
- restoration of metabolic homeostasis 681–4  
 bicarbonate 683–4  
 glucose 681–2  
 naloxone 683  
 oxygen 682–3  
 temperature effect 724  
 ventilation 679
- neonatal seizures *see* seizures
- neonatal sepsis *see* sepsis, neonatal
- neural tube closure 111
- neural tube defects 111–14
- Neurobehavioral Assessment of the Preterm Infant (NAPI) 817–26
- clinical validity 821–2
- development of 818–19
- diverse uses of 826
- examination 819–21
- external validation 825
- limitations 825
- pilot version 817–18
- predictive value 824
- training 825
- neurofibromatosis 202
- neuronal degeneration  
 animal model 37–53
- cell death 48–51  
 apoptosis–necrosis continuum 51–3  
 biphasic 715–16
- hypotension role 98–9
- nitric oxide role 71
- striatal 37–48, 99, 100  
 glutamate transporter defects and 37–41  
 Na,K-ATPase defects and 45–8  
 NMDA receptors and 41–5
- watershed distribution 98–9, 100, 392–3, 416–17
- neuroprotective mechanisms after hypoxic–ischemic injury 715–26
- endogenous responses 717–23  
 cellular factors 718  
 cerebrovascular responses 718–19  
 inhibitory neuromodulators 718  
 neurotrophic factors 719–23
- postnatal hypothermia 102, 415, 723–5  
 during resuscitation/reperfusion 724  
 prolonged cooling 724–5  
 window of opportunity for other therapies 725, 726–7
- neurosonography *see* ultrasonographic imaging
- Nguyen, Ryan 859–60
- nicotine 279–80  
 in breast milk 280  
*see also* smoking during pregnancy
- nitric oxide (NO) 70–2  
 beneficial effects of 70  
 in extended neonatal management 695  
 neuroprotective role 719  
 pathophysiological role of 70–2
- persistent pulmonary hypertension of the newborn treatment  
 641–2  
 follow-up studies 655–6  
 outcomes 655–6  
 toxicity 621
- nitric oxide synthase (NOS) 70–2
- nitroprusside, cardiac output maintenance 697
- nonimmune hydrops 586  
 associated conditions 586, 587
- nonketotic hyperglycinemia (NKH) 398–9  
 EEG recordings 441
- nonstress test (NST) 216–18  
 basis for 216

## 902 Index

- nonstress test (NST) (*cont.*)  
 efficacy 218  
 how to perform 217  
 interpretation 217–18  
 when to perform 216–17
- nucleated red blood cells (NRBCs) 522, 531–4  
 diagnosis 532  
 etiology 532  
 history 531–2  
 mechanisms of increased NRBCs 533  
 meconium staining association 628  
 neurologic injury and 628  
 placental histopathology and 532  
 timing of asphyxia and 534, 543–4
- nutritional support 791–809  
 asphyxiated infants 798  
   recommendations 809  
 enteral feeding 791–5  
   gastric feeding 791–3  
   guidelines 795, 809  
   late introduction of 809  
   necrotizing enterocolitis and 795, 800–2  
   route of 809  
   slow advancement of 809  
   transpyloric feeding 793–5  
 parenteral feeding 795–8  
*see also* necrotizing enterocolitis
- Ohtahara syndrome 772
- olfactory stimulation, hemodynamic effects 501–2
- operative vaginal delivery 138, 267–70  
 fetal indications for 139–40  
 instrumental deliveries 139  
 maternal indications for 139
- opioid abuse 286–8  
 withdrawal 287
- organic acidemias 400–1
- ossification, delayed, IUGR association 157–8
- oxidative phosphorylation 58–9
- oxidative stress, striatal neurodegeneration and 47–8
- oxygen free radicals 68–9  
 inhibitors 708–9
- oxygen therapy  
 maternal 165  
 neonatal resuscitation and 682  
*see also* extracorporeal membrane oxygenation
- oxygenation, fetal 227–8
- oxytocin challenge test 214
- pain relief, during labor 133–4
- pancuronium, intracranial hemorrhage prevention 184
- parasagittal border-zone injury 416–17
- parental interaction, IUGR and 159
- parenteral nutrition 795–8
- IUGR prevention 165
- patent ductus arteriosus (PDA) 455, 702
- PCP abuse 289–90
- perfluorocarbon (PFC) liquid ventilation 643
- perfusion MRI (PMRI) 472
- perinatal asphyxia *see* asphyxia
- perinatal mortality rate (PMR) 212–13
- perinatal telencephalic leukoencephalopathy 420
- periventricular hemorrhage 421  
 seizure etiology 765
- periventricular hemorrhagic venous infarction (PHVI) 451, 455–7
- periventricular leukomalacia (PVL) 101, 178, 182, 420  
 cystic (cPVL) 307  
 EEG recordings 441–2  
 neurosonography 455–47, 458–61  
 outcome 183  
 timing of asphyxia and 546–7
- peroxisomal disorders 400
- peroxynitrite 71
- persistent fetal circulation (PFC) 596
- persistent pulmonary hypertension of the newborn (PPHN) 619, 620–2, 636–56  
 differential diagnosis 637–8  
 outcomes 643–56  
   follow-up studies 644–7  
   with conventional medical therapy 643–4, 652–5  
   with extracorporeal membrane oxygenation 647–55  
   with inhaled nitric oxide 655–6
- pathogenesis 638–40
- seizure etiology 766
- treatment 640–3  
 exogenous surfactant 641  
 extracorporeal membrane oxygenation 642–3, 647–55  
 high-frequency ventilation 641  
 inhaled nitric oxide 641–2, 655–6  
 liquid ventilation 643  
 nonrespiratory interventions 640  
 pharmacologic approaches 642  
 ventilator management 640–1
- phenobarbital  
 intracranial hemorrhage prevention  
   antenatal prevention 185  
   preterm infant 183–4  
 seizure management 775, 776
- phenylketonuria (PKU), maternal 191, 200–1
- phenytoin 775, 776
- phosphocreatine (PCr) 59–61
- phosphodiesterase (PDE), persistent pulmonary hypertension  
 treatment 642
- phosphorylase kinase deficiency 405
- phototherapy, hyperbilirubinemia management 574–5
- placenta  
 growth factors 147  
 indications for placental examinations 519, 520



- IUGR and 149
- preeclampsia and 257
- see also* placental pathology
- placenta abruption 245–7
  - clinical presentation/diagnosis 246
  - complications 247
  - etiology/risk factors 246
  - incidence 246
  - management 246–7
- placenta previa 244–5
  - clinical presentation/diagnosis 244–5
  - complications 245
  - etiology/risk factors 244
    - smoking during pregnancy 244, 280
  - incidence 244
  - management 245
- placental pathology 519–35
  - conditions associated with low uteroplacental blood flow 519–23, 526
    - avascular villi 522
    - chorangiomas 523
    - chorioamnionitis 522
    - fetal placental thrombi 520–2
    - hemorrhagic endovascular pathology 523
    - histopathology 519–20, 532
    - meconium 522, 528–31
    - nucleated red blood cells 522, 531–4
    - terminology 519–20
    - villitis of unknown etiology 522–3
  - epidemiologic studies 523–8
    - Collaborative Perinatal Study (CPS) 523–4
    - differences of opinions 525–6
    - era of cytokines 526–7
    - era of low uteroplacental blood flow 526
    - reliability studies 524
  - need for placental examinations 527–8
  - pathology reports 519, 521
  - timing of asphyxia and 547
  - see also* placenta
- platelet aggregating factor (PAF), role in necrotizing enterocolitis 806
- platelets, timing of asphyxia and 534, 543
- Pneumocystis carinii* pneumonia (PCP) 382, 385–6
- pneumonia, neonatal, chorioamnionitis and 306
- polycythemia 578–82
  - asymptomatic infants 582
  - blood viscosity relationship 579
  - causes of 578
  - definition 578
  - effects of increased hematocrit 578–80
  - effects on neurologic function 580–2
    - long-term sequelae 581–2
    - newborn 580–1
  - incidence 578
  - organ oxygenation relationship 579
  - therapy 582
- Pompe disease 405
- ponderal index 145
- pontosubicular necrosis 418
- porencephaly 120
- positron emission tomography (PET) 446
  - hypoxic–ischemic injury 483–4
- postasphyxial encephalopathy *see* hypoxic–ischemic encephalopathy (HIE)
- posterior fossa hemorrhage 469
- posthemorrhagic ventriculomegaly (PHVM) 181–2
  - diagnosis 181–2
  - management 182
  - outcome 182–3
  - prevention 182
- preeclampsia 256–8
  - cytokine role 527
  - definition 256
  - epidemiology 256–7
  - genetic basis 257–8
  - neonatal outcome 258
  - pathophysiology 257
- premature rupture of membranes (PROM) 131
- preterm (PPROM) 131
  - chorioamnionitis and 304
- prematurity 129
  - associated factors 129–31
    - demographic factors 130
    - obstetrical factors 130–1
    - substance abuse 130
  - brain injury 100–2
    - cortical vs subcortical gray matter 100–1
    - intraventricular hemorrhage 102
    - white-matter injury 101
  - cerebral palsy and 308
  - chorioamnionitis and 306–7
  - incidence 129
  - intracranial hemorrhage and 177–8
    - prevention 183–4
  - labor and delivery management 131–7
    - fetal monitoring 134
    - malpresentation 134–5
    - multiple gestations 134–5
    - route of delivery 134–5
  - periventricular leukomalacia and 178
  - see also* Neurobehavioral Assessment of the Preterm Infant (NAPI); nutritional support
- preterm birth *see* prematurity
- programmed cell death (PCD) *see* apoptosis
- progressive neonatal epileptic syndromes 772–3
- progressive rubella panencephalitis 362
- propionic acidemia (PA) 403
- psychiatric disorders, maternal 198–200

## 904 Index

- psychoeducational ability, asphyxia outcomes 845–9  
 pulmonary arterial disease 703  
 pulmonary hemorrhage, IUGR association 157  
 pulmonary manifestations of asphyxia 16  
 pulmonary parenchymal disease 701–3  
 pyrexia in labor, hyperthermia and 103  
 pyridoxine-dependent seizures 399, 770  
   EEG recordings 441  
   treatment 775  
 pyruvate carboxylase deficiency 401  
 pyruvate dehydrogenase (PDH) deficiency 401
- reactive oxygen species (ROS) 47–8, 68–9  
 renal manifestations of asphyxia 16  
 reperfusion injury 666–7  
   temperature effect 724  
 resuscitation *see* neonatal resuscitation  
 Rett syndrome 405  
 Rhesus disease 201, 573  
   sinusoidal patterns and 237  
 rubella 360–3  
   clinical manifestations of intrauterine infection 361  
   recommendations 362–3  
   risk of neurologic sequelae 361–2  
   transmission to the fetus 361  
   vaccination 360–1, 363
- schizophrenia, maternal 199  
 screening  
   congenital syphilis 364–5  
   drug abuse 292–3  
   fetal well-being 213–14  
   group B streptococcus sepsis 322–3  
   toxoplasmosis 357  
 sedative-hypnotic abuse 288  
 seizures 735–78  
   benign familial neonatal seizures 773  
   classification 737, 738  
   clonic seizures 738–9  
   myoclonic seizures 740–3  
   tonic seizures 739–40  
   consequences of on brain development 777–8  
   context of 773–4  
   diagnosis 735–8  
   clinical criteria 736  
   differential diagnosis 760, 761  
   EEG criteria 748–51  
   subtle seizure activity 736–8  
 EEG applications 425–6, 429, 736  
   brief rhythmic discharges 751  
   ictal EEG patterns 749–50  
   interictal EEG patterns 756–60  
   periodic discharges 750–1  
   seizure criteria 748–51  
   seizure duration and topography 750  
   etiologies 760–73  
   asphyxia 760–3, 838–9  
   cerebrovascular lesions 765–8  
   CNS malformations 768–70  
   drug withdrawal and intoxication 772  
   hypertnatremia 765  
   hypocalcemia 764–5  
   hypoglycemia 764  
   hyponatremia 765  
   inborn errors of metabolism 770–2  
   infection 768  
   meconium staining 616, 763–4  
   incidence related to criteria 756  
   maternal seizure disorder 197–8  
   newborn 12–14, 239  
   folinic acid-responsive seizures 399  
   herpes simplex virus and 370–1  
   isolated seizures 397–401  
   pyridoxine-dependent seizures 399  
   nonepileptic behaviors of neonates 743–8  
   dystonia without EEG seizures 748  
   myoclonus without EEG seizures 746–8  
   tremulousness or jitteriness 743–6  
   prognosis 774–5  
   progressive neonatal epileptic syndromes 772–3  
   subcortical seizures 751–6  
   brainstem release phenomena 752  
   electroclinical dissociation (ECD) 752–6  
   timing of asphyxia 543  
   treatment 415, 775–7  
   discontinuation of drug use 776–7  
   efficacy of 776  
   *see also* epilepsy  
   selective cerebral perfusion (SCAP) 663, 668  
   selective intrapartum chemoprophylaxis (SIC) 323–4  
   selective neonatal chemoprophylaxis (SNC) 324  
   sensorineural hearing loss (SNHL) 621, 622  
   asphyxia outcomes 839–40  
   following persistent pulmonary hypertension of the newborn  
   646–7  
   sensory stimuli, hemodynamic effects 501–2  
 sepsis, neonatal 18, 314–27, 333  
   chorioamnionitis and 306  
   clinical presentation 315, 321  
   diagnosis 315–18, 322  
   early-onset disease 314  
   epidemiology 314, 320  
   etiology 315  
   incidence 315  
   late-onset disease 314  
   organisms 319–27  
   enterococcal group D streptococci 327  
   *Escherichia coli* 325–6  
   group B streptococcus 320–5  
   *Streptococcus pyogenes* (group A streptococcus) 326

- outcome 319, 322  
 prevention 319, 322–5, 347–8  
   chemoprophylaxis 324–5  
   immunoprophylaxis 325  
 risk factors 314–15, 321  
 treatment 318, 322
- shingles 366
- short-chain 3-hydroxyacyl CoA dehydrogenase (SCHAD) deficiency 401–2
- shoulder dystocia 138–9, 263–7  
 complications 265–7  
 definition 264  
 diagnosis 264  
 management 265  
 risk factors 264–5
- sickle-cell disease 201
- single-photon emission computed tomography (SPECT) 446  
 hypoxic-ischemic injury 483–4
- sleep, fetal 214, 217, 218  
 cocaine exposure and 285  
 EEG recordings 427–8, 430, 748  
 ontogeny of sleep stage 430
- small-for-gestational-age (SGA) fetus 145  
 outcome 160–3  
   *see also* intrauterine growth retardation (IUGR)
- smoking during pregnancy 279–81  
 IUGR and 151, 152, 279–80
- solvent abuse 291
- Sotos syndrome 119
- SS-A (Ro) antibodies 205
- SS-B (La) antibodies 205
- Staphylococcus aureus* 343  
 neonatal sepsis 315
- status marmoratus 418
- Streptococcus agalactiae* *see* group B streptococcus
- Streptococcus pneumoniae*, neonatal meningitis 336
- Streptococcus pyogenes* *see* group A streptococcus
- striatal neurodegeneration, animal models 37–48, 99, 100  
 glutamate transporter defects and 37–41  
 Na,K-ATPase defects and 45–8  
 NMDA receptors and 41–5
- stroke 17–18  
 EEG recordings 442  
   *see also* infarction
- subarachnoid hemorrhage, ultrasonography 459
- subdural hemorrhage 175
- substance abuse 199–200, 274–94  
 adulterants, substitutes and contaminants 291–2  
 cocaine 282–6  
 drug distribution in pregnancy 274–5  
 EEG recordings 442  
 general effects during pregnancy 275  
 IUGR and 151–2  
 LSD 290  
 marijuana 281–2
- methodologic problems 275–6
- opioids 286–8
- PCP 289–90
- polydrug abuse 275
- preterm birth and 130
- screening 292–3
- sedative-hypnotics 288
- seizure etiology 772
- sympathomimetics 288–9
- volatile substances 290–1  
   *see also* alcohol abuse; smoking during pregnancy
- sudden infant death syndrome (SIDS), cocaine exposure and 285
- sulfite oxidase deficiency 399
- suppression short T1 inversion recovery imaging (STIR) 472, 473
- surfactant therapy  
 hemodynamic effects 500–1  
 in extended neonatal management 694–5  
 persistent pulmonary hypertension of the newborn treatment 641
- sympathomimetic abuse 288–9
- symphysis-fundus height (SFH) 153
- syphilis, congenital 363–6  
 diagnosis 363–4, 365  
 early congenital syphilis 364  
 manifestations 364  
 recommendations 364–6  
 treatment 365–6
- systemic lupus erythematosus (SLE) 202–6  
 effect on fetus 204–5  
 medications during pregnancy 203–4  
 pregnancy effect on course of 203  
 pregnancy management 205–6
- tachycardia 136, 234  
 in hydrops fetalis 588
- talozoline, persistent pulmonary hypertension of the newborn treatment 642
- termination period 111
- thalamus  
 hemorrhage 176  
 lesions 417–18  
 animal model 50
- thalassemia 201
- thiamine deficiency 150
- thrombocytopenia 176
- thyroid disease, maternal 194–6  
 IUGR association 157–8
- thyrotoxicosis, neonatal 195–6
- time-of-flight spectroscopy 492–3, 508–9
- tobacco smoking *see* smoking during pregnancy
- tocolytic therapy 138  
 contraindications 132
- tolazoline, persistent pulmonary hypertension treatment 642
- tonic seizures 739–40
- topiramate, seizure management 776

## 906 Index

- TORCH, seizure etiology 768
- total parenteral nutrition (TNP) 796–7
- toxoplasmosis, congenital 355–8
- outcome 356–7
- infants asymptomatic at birth 356
- infants symptomatic at birth 356–7
- prenatal diagnosis 357
- prevention 358
- recommendations 357–8
- screening 357
- training *see* medical training
- tranexamic acid, intracranial hemorrhage prevention 184
- transforming growth factor- $\beta$ , neuroprotective role 723
- transpyloric feeding 793–5
- tremors 743–6
- Treponema pallidum see* syphilis
- tricarboxylic acid cycle defects 401
- trifunctional protein (TFP) deficiency 260–1
- tuberous sclerosis 202, 773
- twin-to-twin transfusion syndrome, anemia and 157
- ulegryria 416
- ultrasonographic imaging 414, 446, 447–71
- anterior fontanel approach 447–8
- chorioamnionitis 304
- germinal matrix/intraventricular hemorrhage 449–55
- hypoxic–ischemic injury 457–9, 464
- limitations 459–71
- mastoid view 448
- neonatal meningitis 340
- periventricular leukomalacia 455–7, 458–61
- posterior fontanel view 448
- timing of asphyxia 546
- see also* Doppler ultrasound
- umbilical cord
- compression during labor 135
- management 137
- gas analysis 240
- meconium-induced vascular necrosis 529, 530
- prolapse 6
- urea cycle disorders 400, 404
- Ureaplasma urealyticum*, chorioamnionitis 305
- uterine abnormalities
- Couvellaire uterus 247
- preterm birth and 130
- uterine contractions
- contraction stress test (CST) 214–15
- fetal asphyxia and 91–2
- experimental studies 92
- fetal heart rate and 136–7, 233–4
- hyperstimulation 136
- uterine rupture
- complications of 250
- risk during vaginal birth after cesarean section 249
- vaccination
- group B streptococcus 325
- rubella 360–1, 363
- vacuum extraction 267–70
- vaginal birth after previous cesarean section (VBAC) 248–51
- candidate selection 248–9
- counseling patients 249
- labor management 249–50
- uterine rupture complications 250
- uterine rupture risk 249
- vaginal delivery
- operative 138
- fetal indications for 139–40
- instrumental deliveries 139
- maternal indications for 139
- shoulder dystocia 138–9
- preterm fetus 134–5
- see also* vaginal birth after previous cesarean section (VBAC)
- varicella-zoster immune globulin (VZIG) 368
- varicella-zoster virus (VZV) 366–8
- congenital varicella syndrome 366–8
- recommendations 368
- vasa previa 247–8
- clinical presentation/diagnosis 247–8
- complications 248
- etiology/risk factors 247
- incidence 247
- management 248
- vascular malformations 120–3
- arteriovenous malformations (AVMs) 121
- carotid artery malformations 122–3
- congenital aneurysms 122
- hemangioblastoma 122
- vein of Galen malformation 121–2, 176
- vein of Galen malformation 121–2, 176
- venous occlusions 420
- venous sinus thrombosis 420
- ventilation
- extended care 692–5
- gentle ventilation 641
- high-frequency ventilation (HFV) 641, 693–4
- hyperventilation 621, 640, 644, 693
- cerebral edema management 704–5
- neonatal resuscitation 679
- ventilator management 640–1
- ventriculitis 341
- very long-chain acyl CoA dehydrogenase (VLCAD) deficiency 401–2
- vibroacoustic stimulation (VAS) 218–19
- villitis of unknown etiology (VUE) 522–3
- vision loss, asphyxia outcomes 839
- visual stimulation, hemodynamic effects 501
- vitamin E
- intracranial hemorrhage prevention 184
- necrotizing enterocolitis and 805

Cambridge University Press

0521806917 - Fetal and Neonatal Brain Injury: Mechanisms, Management and the Risks of Practice, Third Edition

Edited by David K. Stevenson, William E. Benitz, and Philip Sunshine

Index

[More information](#)

- vitamin K
  - intracranial hemorrhage prevention 185
  - maternal seizure disorder management 198
- volatile substance abuse 290–1
- von Hippel–Lindau syndrome 122, 202
  
- watershed distribution of neuronal injury 98–9, 100, 392–3, 416–17, 455
  
- white-matter injury 101, 420–1
  - insulin-like growth factors and 721–2
  - intraventricular hemorrhage and 102
  
- X cells 520
  
- Zellweger syndrome 400
- zinc deficiency 150